As a cornerstone therapy, inhaled bronchodilators (short- and long-acting combined) that target β2-adrenoceptors (β2ARs), which are G protein-coupled receptors (GPCRs) expressed on human airway smooth muscle (HASM) cells, reverse or prevent airflow obstruction—a root cause of asthma morbidity and mortality (3, 4). Here, ADRA1A is linked to asthma.